

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MADGE *et al.*

Application No.: 10/659,178

Filed: September 9, 2003

For: Boronic Acid Salts

Confirmation No.: 7469

Art Unit: 1621

Examiner: Yevgeny Valenrod

Atty. Docket: 2451.0090006/BJD/GER

Declaration Under 37 C.F.R. § 1.132 Of Dr. Anthony Kennedy

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

I, Anthony James Kennedy, declare and state as follows:

1. I am the Vice President of Development at Trigen Limited. Trigen Limited is the assignee of this patent application. I am also a co-inventor of the subject matter claimed in this patent application.

2. I received a B.Sc. in Biochemistry from Surrey University, an M.Sc. in Neurochemistry from the Institute of Psychiatry, London University, and a Ph.D. in Biochemistry from the Institute of Ophthalmology, London University. I was also an MRC Post-Doctoral Research Fellow at the School of Pharmacy, London University. A copy of my *curriculum vitae* is attached.

3. I have reviewed and am familiar with the Office Action dated February 5, 2007, the Amendment and Reply filed March 20, 2007, and the final Office Action dated May 23, 2007. I have also reviewed and am familiar with the application as filed and the claims as amended in the Amendment and Reply filed August 17, 2007.

4. I have also reviewed and am familiar with the documents cited by the Examiner in the final Office Action: Rewinkel *et al.*, *Curr. Pharm. Design* 5:1043 (1999) (hereinafter "Rewinkel"); de Nanteuil *et al.*, U.S. Patent No. 5,814,622 (hereinafter "de Nanteuil"); and Adams *et al.*, U.S. Patent No. 5,780,454 (hereinafter "Adams").

Considered.
YV